Title: Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair.
Journal: Nature genetics 20180801
Title: PARP inhibitors: A new era of targeted therapy.
Journal: Maturitas 20150501
Title: Structural basis for the inhibition of poly(ADP-ribose) polymerases 1 and 2 by BMN 673, a potent inhibitor derived from dihydropyridophthalazinone.
Journal: Acta crystallographica. Section F, Structural biology communications 20140901
Title: Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
Journal: Cancer research 20121101
Title: Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination.
Journal: Nature structural & molecular biology 20101001
Title: Wang B, et al. Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido,3,2-dephthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent. J Med Chem. 2016 Jan 14;59(1):335-57.
Title: Shen Y, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency.Clin Cancer Res. 2013 Sep 15;19(18):5003-15.
